Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

Biochemical Pharmacology

Volumn 83, Issue 12, 2012, Pages 1583-1590

  Schafer, Peter ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

Apremilast; Phosphodiesterase 4 inhibitor; Psoriasis; Psoriatic arthritis

Indexed keywords

APREMILAST; CYCLIC AMP; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 23; PHOSPHODIESTERASE IV; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; DENDRITIC CELL; DIARRHEA; DRUG INDUCED HEADACHE; DRUG MECHANISM; HUMAN; IN VITRO STUDY; INFLAMMATION; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 84860175869     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.01.001     Document Type: Note

References (68)

1. S.K. Kurd, and J.M. Gelfand The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004 J Am Acad Dermatol 60 2009 218 224
2. M. Augustin, K. Reich, G. Glaeske, I. Schaefer, and M. Radtke Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany Acta Derm Venereol 90 2010 147 151
3. A. Gottlieb, N.J. Korman, K.B. Gordon, S.R. Feldman, M. Lebwohl, and J.Y. Koo Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics J Am Acad Dermatol 58 2008 851 864
4. D.D. Gladman, C. Antoni, P. Mease, D.O. Clegg, and P. Nash Psoriatic arthritis: epidemiology, clinical features, course, and outcome Ann Rheum Dis 64 Suppl. 2 2005 ii14 ii17
5. M.A. Lowes, A.M. Bowcock, and J.G. Krueger Pathogenesis and therapy of psoriasis Nature 445 2007 866 873
6. J. Fuentes-Duculan, M. Suarez-Farinas, L.C. Zaba, K.E. Nograles, K.C. Pierson, and H. Mitsui A subpopulation of CD163-positive macrophages is classically activated in psoriasis J Invest Dermatol 130 2010 2412 2422
7. A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850
8. A.D. Burden, M. Hilton Boon, J. Leman, H. Wilson, R. Richmond, and A.D. Ormerod Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance BMJ 341 2010 c5623
9. A. Menter, N.J. Korman, C.A. Elmets, S.R. Feldman, J.M. Gelfand, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents J Am Acad Dermatol 61 2009 451 485
10. C.N. Serhan, S. Krishnamoorthy, A. Recchiuti, and N. Chiang Novel anti-inflammatory - pro-resolving mediators and their receptors Curr Top Med Chem 11 2011 629 647
11. I.R. Williams, and T.S. Kupper Immunity at the surface: homeostatic mechanisms of the skin immune system Life Sci 58 1996 1485 1507
12. F.O. Nestle, D.H. Kaplan, and J.H. Barker Psoriasis N Engl J Med 361 2009 496 509
13. L.C. Zaba, J. Fuentes-Duculan, N.J. Eungdamrong, L.M. Johnson-Huang, K.E. Nograles, and T.R. White Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis J Allergy Clin Immunol 125 2010 1261 1268
14. K. Uyemura, M. Yamamura, D.F. Fivenson, R.L. Modlin, and B.J. Nickoloff The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response J Invest Dermatol 101 1993 701 705
15. L.C. Zaba, J. Fuentes-Duculan, N.J. Eungdamrong, M.V. Abello, I. Novitskaya, and K.C. Pierson Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells J Invest Dermatol 129 2009 79 88
16. N. Yawalkar, G.G. Tscharner, R.E. Hunger, and A.S. Hassan Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis J Dermatol Sci 54 2009 99 105
17. C. Johansen, P.A. Usher, R.B. Kjellerup, D. Lundsgaard, L. Iversen, and K. Kragballe Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin Br J Dermatol 160 2009 319 324
18. S.P. Raychaudhuri, S.K. Raychaudhuri, and M.C. Genovese IL-17 receptor and its functional significance in psoriatic arthritis Mol Cell Biochem 2011
19. G. Piskin, R.M.R. Sylva-Steenland, J.D. Bos, and M.B.M. Teunissen In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin J Immunol 176 2006 1908 1915
20. M.A. Lowes, F. Chamian, M.V. Abello, J. Fuentes-Duculan, S.L. Lin, and R. Nussbaum Increase in TNF-á and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a) Proc Natl Acad Sci USA 102 2005 19057 19062
21. L.M. Austin, M. Ozawa, T. Kikuchi, I.B. Walters, and J.G. Krueger The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients J Invest Dermatol 113 1999 752 759
22. A.M. Lin, C.J. Rubin, R. Khandpur, J.Y. Wang, M. Riblett, and S. Yalavarthi Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis J Immunol 187 2011 490 500
23. A. Henno, S. Blacher, C.A. Lambert, C. Deroanne, A. Noel, and C. Lapiere Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis J Dermatol Sci 57 2010 162 169
24. N. Dalbeth, B. Pool, T. Smith, K.E. Callon, M. Lobo, and W.J. Taylor Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion Arthritis Res Ther 12 2010 R164
25. M. Conti, W. Richter, C. Mehats, G. Livera, J.Y. Park, and C. Jin Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling J Biol Chem 278 2003 5493 5496
26. C.H. Serezani, M.N. Ballinger, D.M. Aronoff, and M. Peters-Golden Cyclic AMP: master regulator of innate immune cell function Am J Respir Cell Mol Biol 39 2008 127 132
27. M.D. Houslay, P. Schafer, and K.Y. Zhang Keynote review: phosphodiesterase-4 as a therapeutic target Drug Discov Today 10 2005 1503 1519
28. L.C. Wright, J. Seybold, A. Robichaud, I.M. Adcock, and P.J. Barnes Phosphodiesterase expression in human epithelial cells Am J Physiol Lung Cell Mol Physiol 275 4 Pt 1 1998 L694 L700
29. M.C. Shepherd, G.S. Baillie, D.I. Stirling, and M.D. Houslay Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells Br J Pharmacol 142 2004 339 351
30. E. Bjorgo, and K. Tasken Role of cAMP phosphodiesterase 4 in regulation of T-cell function Crit Rev Immunol 26 2006 443 451
31. H.C. Heystek, A-C. Thierry, P. Soulard, and C. Moulon Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity Int Immunol 15 2003 827 835
32. G. Schett, V.S. Sloan, R.M. Stevens, and P. Schafer Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases Ther Adv Musculoskelet Dis 2 2010 271 278
33. H. Tenor, E. Hedbom, H.J. Hauselmann, C. Schudt, and A. Hatzelmann Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes - functional importance of phosphodiesterase 4 Br J Pharmacol 135 2002 609 618
34. F. Mori, S. Perez-Torres, R. De Caro, A. Porzionato, V. Macchi, and J. Beleta The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D J Chem Neuroanat 40 2010 36 42
35. D. Claveau, S.L. Chen, S. O'Keefe, D.M. Zaller, A. Styhler, and S. Liu Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2- hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor J Pharmacol Exp Ther 310 2004 752 760
36. A. Eigler, B. Siegmund, U. Emmerich, K.H. Baumann, G. Hartmann, and S. Endres Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production J Leukoc Biol 63 1998 101 107
37. M.D. Houslay, and D.R. Adams PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization Biochem J 370 Pt 1 2003 1 18
38. A.C. Zambon, L. Zhang, S. Minovitsky, J.R. Kanter, S. Prabhakar, and N. Salomonis Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A Proc Natl Acad Sci USA 102 2005 8561 8566
39. M.D. Houslay Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown Trends Biochem Sci 35 2010 91 100
40. S.J. MacKenzie, and M.D. Houslay Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element- binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells Biochem J 347 2000 571 578
41. J. Navarro, C. Punzon, J.L. Jimenez, E. Fernandez-Cruz, A. Pizarro, and M. Fresno Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT J Virol 72 1998 4712 4720
42. J.L. Jimenez, C. Punzon, J. Navarro, M.A. Munoz-Fernandez, and M. Fresno Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation J Pharmacol Exp Ther 299 2001 753 759
43. N. Takahashi, T. Tetsuka, H. Uranishi, and T. Okamoto Inhibition of the NF-kappaB transcriptional activity by protein kinase A Eur J Biochem 269 2002 4559 4565
44. V. Ollivier, G.C. Parry, R.R. Cobb, D. de Prost, and N. Mackman Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells J Biol Chem 271 1996 20828 20835
45. L. Gobejishvili, S. Barve, S. Joshi-Barve, C. McClain, and P.D.E4B. Enhanced expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease Am J Physiol Gastrointest Liver Physiol 295 2008 G718 G724
46. G.C. Parry, and N. Mackman Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription J Immunol 159 1997 5450 5456
47. A.L. Hertz, A.T. Bender, K.C. Smith, M. Gilchrist, P.S. Amieux, and A. Aderem Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages Proc Natl Acad Sci USA 106 2009 21978 21983
48. S. Videla, J. Vilaseca, C. Medina, M. Mourelle, F. Guarner, and A. Salas Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis J Pharmacol Exp Ther 316 2006 940 945
49. A.B. Gottlieb, B. Strober, J.G. Krueger, P. Rohane, J.B. Zeldis, and C.C. Hu An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast Curr Med Res Opin 24 2008 1529 1538
50. G. Schett, J. Wollenhaupt, K. Papp, R. Joos, K.L. De Vlam, and J.F. Rodrigures Apremilast is active in the treatment of psoriatic arthritis (PsA) [abstract 1258] Presented at: ACR/ARHP 2009 annual scientific sessions October 17-21, 2009; Philadelphia, PA 2009
51. R. Nazarian, and J.M.A.N-2728 Weinberg a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis Curr Opin Investig Drugs 10 2009 1236 1242
52. A. Keshavarzian, E. Mutlu, J.P. Guzman, C. Forsyth, and A. Banan Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease Expert Opin Investig Drugs 16 2007 1489 1506
53. H-W. Man, P. Schafer, L.M. Wong, R.T. Patterson, L.G. Corral, and H. Raymon Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2- methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor J Med Chem 52 2009 1522 1524
54. P.H. Schafer Effects of apremilast on innate and adaptive immune responses [poster] Presented at: Annual Meeting of the European Society for Dermatological Research September 7-12, 2011; Barcelona, Spain 2011
55. P.H. Schafer, A. Parton, A.K. Gandhi, L. Capone, M. Adams, and L. Wu Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis Br J Pharmacol 159 2010 842 855
56. F.E. McCann, A.C. Palfreeman, M. Andrews, D.P. Perocheau, J.J. Inglis, and P. Schafer Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis Arthritis Res Ther 12 2010 R107
57. J.A. van Roon, and F.P. Lafeber Role of interleukin-7 in degenerative and inflammatory joint diseases Arthritis Res Ther 10 2008 107
58. S.A. Hartgring, C.R. Willis, D. Alcorn, L.J. Nelson, J.W. Bijlsma, and F.P. Lafeber Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators Arthritis Rheum 62 2010 2716 2725
59. M. Rihl, H. Kellner, W. Kellner, C. Barthel, D.T. Yu, and P.P. Tak Identification of interleukin-7 as a candidate disease mediator in spondylarthritis Arthritis Rheum 58 2008 3430 3435
60. J.A. van Roon, K. Jacobs, S. Verstappen, J. Bijlsma, and F. Lafeber Reduction of serum interleukin 7 levels upon methotrexate therapy in early rheumatoid arthritis correlates with disease suppression Ann Rheum Dis 67 2008 1054 1055
61. D. Salopek, D. Grcevic, V. Katavic, N. Kovacic, I.K. Lukic, and A. Marusic Increased bone resorption and osteopenia are a part of the lymphoproliferative phenotype of mice with systemic over-expression of interleukin-7 gene driven by MHC class II promoter Immunol Lett 121 2008 134 139
62. S.R. Pickens, N.D. Chamberlain, M.V. Volin, R.M. Pope, N.E. Talarico, and A.M. Mandelin Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis Arthritis Rheum 63 2011 2884 2893
63. Capone L, Rogovitz A, Gandhi AK. Schafer PH. Anti-inflammatory activity of apremilast against T cells, chondrocytes, and rheumatoid arthritis synovial fibroblasts in vitro [abstract 1844]. Available at: < http://acr.confex.com/ acr/2011/webprogram/Paper23923.html > [accessed 14.12.11].
64. A. Robichaud, P.B. Stamatiou, S.L. Jin, N. Lachance, D. Macdonald, and F. Laliberte Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis J Clin Invest 110 2002 1045 1052
65. P. Schafer Widening the therapeutic window with CC-10004, a novel PDE4 inhibitor Presented at: 2003 Strategic Research Institute conference on phosphodiesterases in disease conference November 13-14, 2003; Princeton, NJ 2003
66. B.T. Au, M.M. Teixeira, P.D. Collins, and T.J. Williams Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol Br J Pharmacol 123 1998 1260 1266
67. K. Papp, J.B. Zeldis, P. Rohane, and D. Thaci A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis [abstract P2614] J Am Acad Dermatol 58 2008 AB3
68. K. Papp, A. Hu, and R.M. Day Oral apremilast is active in the treatment of moderate to severe plaque psoriasis: results from a phase 2b, randomized, controlled study (PSOR-005) [poster 273] Presented at: annual meeting of the European Society for Dermatological Research September 7-12, 2011; Barcelona, Spain 2011